Associated Papers
Sporadic medullary thyroid carcinoma with a rare RET transmembrane domain mutation (A641R) that responds to selpercatinib.
Fukuda N et al.
The Oncologist, 2025
Comprehensive Assessment of Indian Variations in the Druggable Kinome Landscape Highlights Distinct Insights at the Sequence, Structure and Pharmacogenomic Stratum.
Panda G et al.
Frontiers in Pharmacology, 2022
35865963 (PubMed )
Supplement: Table12.xlsx › Sheet1
GLOBAL ENDOCRINOLOGY: Geographical variation in the profile of RET variants in patients with medullary thyroid cancer: a comprehensive review.
Maciel RMB et al.
European Journal of Endocrinology, 2021
iFish: predicting the pathogenicity of human nonsynonymous variants using gene-specific/family-specific attributes and classifiers.
Wang M et al.
Scientific Reports, 2016
27527004 (PubMed )
Supplement: srep31321-s4.xls › SwissvarFilteredMix
Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma.
Santarpia L et al.
Journal of Internal Medicine, 2009
Characterization of the RET protooncogene transmembrane domain mutation S649L associated with nonaggressive medullary thyroid carcinoma.
Colombo-Benkmann M et al.
European Journal of Endocrinology, 2008
Self-association of the transmembrane domain of RET underlies oncogenic activation by MEN2A mutations.
Kjaer S et al.
Oncogene, 2006
Three novel mutations in the RET proto-oncogene.
Kalinin VN et al.
Journal of Molecular Medicine (berlin, Germany), 2001
Select a paper to view details